TY  - JOUR
AU  - Lerche, Stefanie
AU  - Schulte, Claudia
AU  - Srulijes, Karin
AU  - Pilotto, Andrea
AU  - Rattay, Tim W
AU  - Hauser, Ann-Kathrin
AU  - Stransky, Elke
AU  - Deuschle, Christian
AU  - Csoti, Ilona
AU  - Lachmann, Ingolf
AU  - Zetterberg, Henrik
AU  - Liepelt-Scarfone, Inga
AU  - Gasser, Thomas
AU  - Maetzler, Walter
AU  - Berg, Daniela
AU  - Brockmann, Kathrin
TI  - Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.
JO  - Movement disorders
VL  - 32
IS  - 12
SN  - 0885-3185
CY  - New York, NY
PB  - Wiley
M1  - DZNE-2020-06000
SP  - 1780-1783
PY  - 2017
AB  - A proportion of idiopathic Parkinson's disease patients (PDidiopathic ) with dementia show altered CSF profiles of amyloid β (Aβ) and Tau. PD patients with Glucocerebrosidase (GBA) mutations (PDGBA ) present with even more cognitive decline than seen in PDidiopathic .The objective of this study was to evaluate whether CSF profiles of Aβ and tau are associated with the prominent cognitive impairment in PDGBA .CSF levels of Aβ1-42 , t-Tau, p-Tau, and total alpha-synuclein were assessed in 479 participants (50 PDGBA , 308 PDidiopathic , 121 healthy controls).Older age was associated with cognitive impairment in PDGBA and PDidiopathic . Despite prominent cognitive impairment, PDGBA showed similar CSF levels of Aβ1-42 , t-Tau, and p-Tau as seen in healthy controls. In contrast, lower levels of Aβ1-42 and higher levels of t-Tau and p-Tau were associated with worse cognitive performance in PDidiopathic .The prominent cognitive impairment in PDGBA seems not primarily associated with Aβ and Tau profiles in CSF. © 2017 International Parkinson and Movement Disorder Society.
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Cognition Disorders: etiology
KW  - Female
KW  - Glucosylceramidase: genetics
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation: genetics
KW  - Neuropsychological Tests
KW  - Parkinson Disease: cerebrospinal fluid
KW  - Parkinson Disease: complications
KW  - Parkinson Disease: genetics
KW  - Peptide Fragments: cerebrospinal fluid
KW  - Retrospective Studies
KW  - Severity of Illness Index
KW  - Statistics, Nonparametric
KW  - Young Adult
KW  - tau Proteins: cerebrospinal fluid
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
KW  - amyloid beta-protein (1-42) (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
KW  - Glucosylceramidase (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:29094781
DO  - DOI:10.1002/mds.27199
UR  - https://pub.dzne.de/record/139678
ER  -